Articles

Although small, the US Food and Drug Administration (FDA) has identified an increased risk for developing anaplastic large cell lymphoma (ALCL) in the scar capsule adjacent to breast implants. Because the risk is small, nurses can help assure women that FDA-approved breast implants are safe when used correctly.

 

Everolimus plus octreotide LAR increases median progression-free survival over octreotide LAR alone in patients with advanced neuroendocrine tumors (NETs), according to the updated results of the RAD001 In Advanced Neuroendocrine Tumors (RADIANT-2) trial presented at the 2011 Gastrointestinal Cancers Symposium (Abstract 159).

 

Nimotuzumab shows the potential to improve both progression-free survival (PFS) and overall survival (OS) in patients with epidermal growth factor receptor (EGFR)-positive gastric cancer, according to results of a phase 2 randomized trial presented at the Gastrointestinal Cancers Symposium.

 

By repeating therapy cycles, clivatuzumab tetraxetan labeled with ⁹⁰Y plus low-dose gemcitabine improve overall survival (OS) over single-cycle therapy in patients with locally advanced or metastatic pancreatic cancer, according to updated data presented at the Gastrointestinal Cancers Symposium. Researchers also found that as the ⁹⁰Y labeld clivatuzumab tetraxetan dose increased so did median OS.

 

 

Two-thirds of patients achieved stable disease with sorafenib after resistance to imatinib and sunitinib treatment for gastrointestinal stromal tumors (GIST), according to a phase 2 trial to be presented at the Gastrointestinal Cancers Symposium.

 

 

New empirical evidence linking confusion about the multiple screening options for colorectal cancer with a reduced likelihood of adherence to screening guidelines should help oncology nurses tailor information when involved in patient education and outreach activities. The cross-sectional study found that patients confused about their options were 1.8 times more likely to be nonadherent with screening recommendations (Cancer Epidemiol Biomarkers Prev. 2010;19:2821-2825).

 

One year of bevacizumab added to 6 months of leucovorin/fluorouracil/oxaliplatin (mFOLFOX6) does not significantly prolong disease-free survival (DFS) in stages II and III colon cancer, according to recently released results of the National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol C-08 (J Clin Oncol. 2011;29:11-16). The study did find, however, a significant transient effect during bevacizumab exposure.